Literature DB >> 19706242

Transcatheter closure of patent ductus arteriosus using the amplatzer duct occluder in infants under 1 year of age.

Rafael Parra-Bravo1, Arturo Cruz-Ramírez, Víctor Rebolledo-Pineda, Jorge Robles-Cervantes, Alejandro Chávez-Fernández, Luisa Beirana-Palencia, Laura Jiménez-Montufar, María de Jesús Estrada-Loza, José Estrada-Flores, Nelson Báez-Zamudio, Mariano Escobar-Ponce.   

Abstract

INTRODUCTION AND
OBJECTIVES: Percutaneous closure of patent ductus arteriosus (PDA) is a well-established technique. We evaluated the usefulness of the Amplatzer duct occluder for the percutaneous closure of patent ductus arteriosus in 29 children under 1 year of age.
METHODS: The patients' mean age was 8.9+/-2.8 months and their mean weight was 6.4+/-1.5 kg. In addition, 24.1% of patients were aged 6 months or less and 17.2% weighed 5 kg or less. All completed follow-up (0.5-36 months).
RESULTS: The minimum PDA diameter was 3.16+/-1.24 mm. The device was implanted successfully in 26 patients (89.6%). Failures were due to either the device migrating to the descending aorta, persistent moderate leakage, or to difficulty in the advancement of the device. No deaths were associated with the procedure. Three major complications occurred in two patients (10.3%). Aortography showed initial total occlusion in 65.5% of patients. At 3-month follow-up, total occlusion was observed in 96.1% of patients. Ultimately, closure was achieved successfully in 25 of the 29 patients (86.2%). During follow-up, four patients exhibited mild left pulmonary artery stenosis and one exhibited mild stenosis of the descending aorta.
CONCLUSIONS: In children under 1 year of age, percutaneous closure of patent ductus arteriosus using an Amplatzer occluder was a safe and effective procedure. It is possible that improvements in the design of the occluder could decrease the complication rate.

Entities:  

Mesh:

Year:  2009        PMID: 19706242

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  6 in total

1.  Transcatheter closure of symptomatic arterial duct in infants younger than 1 year old.

Authors:  Biagio Castaldi; Giuseppe Santoro; Gianpiero Gaio; Maria Teresa Palladino; Carola Iacono; Maria Giovanna Russo
Journal:  Pediatr Cardiol       Date:  2012-05-26       Impact factor: 1.655

2.  Transcatheter Closure of Arterial Duct in Infants < 6 kg: Amplatzer Duct Occluder Type I vs Amplatzer Duct Occluder II Additional Sizes.

Authors:  Giuseppe Santoro; Mario Giordano; Gianpiero Gaio; Maria Teresa Palladino; Giovanbattista Capozzi; Carola Iacono; Maria Giovanna Russo
Journal:  Pediatr Cardiol       Date:  2018-02-17       Impact factor: 1.655

3.  Experience with percutaneous closure of ductus arteriosus using the Amplatzer duct occluder in 243 consecutive patients and long-term results-A single centre study.

Authors:  Mostafa Behjati-Ardakani; Mohammad Amin Behjati-Ardakani; Mehdi Hadadzadeh; Seyed Hossein Moshtaghion; Mohammadtaghi Sarebanhassanabadi
Journal:  Niger Med J       Date:  2014-09

4.  Fate of the Left Pulmonary Artery and Thoracic Aorta After Transcatheter Patent Ductus Arteriosus Closure in Low Birth Weight Premature Infants.

Authors:  Dor Markush; Jennifer C Tsing; Surbhi Gupta; Nicole C Berndsen; Geena Radville; Ruchira Garg; Evan M Zahn; Myriam Almeida-Jones
Journal:  Pediatr Cardiol       Date:  2021-01-04       Impact factor: 1.655

5.  Miniinvasive hybrid procedure for device migration after percutaneous closure of persistent arterial duct: a case report.

Authors:  Ireneusz Haponiuk; Maciej Chojnicki; Radoslaw Jaworski; Mariusz Steffek; Jacek Juscinski; Irena Zabolska; Aneta Sendrowska; Katarzyna Gierat-Haponiuk
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2012-05-29       Impact factor: 1.195

6.  Long-term results of transcatheter closure of patent ductus arteriosus in infants using amplatzer duct occluder.

Authors:  Mostafa Behjati-Ardakani; Mohammad-Amin Behjati-Ardakani; Seyed-Habibolla Hosseini; Noormohammad Noori
Journal:  Iran J Pediatr       Date:  2013-08       Impact factor: 0.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.